Ferguson Wellman Capital Management Inc. Has $26.68 Million Holdings in Cencora, Inc. (NYSE:COR)

Ferguson Wellman Capital Management Inc. lessened its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 7.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 118,520 shares of the company's stock after selling 10,201 shares during the period. Ferguson Wellman Capital Management Inc. owned approximately 0.06% of Cencora worth $26,676,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Rise Advisors LLC acquired a new position in shares of Cencora during the 1st quarter worth about $25,000. New Millennium Group LLC acquired a new position in shares of Cencora during the 2nd quarter worth about $26,000. TCTC Holdings LLC acquired a new position in shares of Cencora during the 1st quarter worth about $29,000. TFO Wealth Partners LLC acquired a new position in shares of Cencora during the 1st quarter worth about $30,000. Finally, MFA Wealth Advisors LLC acquired a new position in shares of Cencora during the 2nd quarter worth about $30,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on COR. JPMorgan Chase & Co. upped their price target on Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a report on Wednesday, August 21st. Wells Fargo & Company upped their price target on Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a report on Thursday, August 1st. Robert W. Baird cut their price target on Cencora from $287.00 to $283.00 and set an "outperform" rating for the company in a report on Friday, September 6th. Bank of America reaffirmed a "neutral" rating and issued a $245.00 price target (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Finally, StockNews.com cut Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $259.44.

Cencora Price Performance

Shares of COR traded up $1.79 during mid-day trading on Friday, reaching $237.43. The company had a trading volume of 1,210,073 shares, compared to its average volume of 1,423,747. Cencora, Inc. has a twelve month low of $182.75 and a twelve month high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The company's 50-day moving average is $232.38 and its 200-day moving average is $231.06. The company has a market capitalization of $47.36 billion, a P/E ratio of 25.98, a P/E/G ratio of 1.40 and a beta of 0.44.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion during the quarter, compared to analysts' expectations of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. Cencora's quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.92 EPS. On average, equities analysts anticipate that Cencora, Inc. will post 13.63 EPS for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were given a dividend of $0.51 per share. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.86%. Cencora's dividend payout ratio (DPR) is presently 22.32%.

Insider Buying and Selling

In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the sale, the insider now directly owns 19,980,000 shares in the company, valued at $4,806,388,800. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the transaction, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.80% of the stock is owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.